Skip to main content
Mabion S.A. logo

Mabion S.A. — Investor Relations & Filings

Ticker · MAB ISIN · PLMBION00016 LEI · 259400KG5JVQPPZL6X53 WAR Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2026-06-18 Regulatory Filings
Country PL Poland
Listing WAR MAB

About Mabion S.A.

https://www.mabion.eu/en/

Mabion S.A. is an integrated Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services for the development and manufacturing of protein-based biotherapeutics. The company specializes in monoclonal antibodies and biosimilars, offering a complete workflow from cell line development and banking to process optimization and large-scale GMP manufacturing. Core competencies include upstream processing using mammalian cell cultures, downstream purification involving chromatography and viral clearance, and technology transfer for scale-up. Mabion partners with pharmaceutical and biotechnology companies to support both clinical and commercial supply, streamlining the path from gene to final drug product.

Recent filings

Filing Released Lang Actions
Przedłużenie umowy dotyczącej komercyjnej produkcji kontraktowej na rzecz Novavax, Inc. - Content (EN)
Regulatory Filings Classification · 95% confidence The document is a short report (about 1,525 characters) announcing the extension of a commercial manufacturing agreement between Mabion S.A. and Novavax, Inc. It references previous current reports and sets out terms of the amendment and the continued cooperation. There are no financial statements or detailed financial performance data included, nor is it a transcript or detailed presentation. The document concerns an operational update regarding a contract extension, which is a regulatory announcement. The document is not an earnings release, annual report, or financial report, nor a board or management change announcement. Given the content and the reference to Market Abuse Regulation disclosure, the document fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit into other more specific categories.
2026-06-18 English
Przedłużenie umowy dotyczącej komercyjnej produkcji kontraktowej na rzecz Novavax, Inc. - Content (PL)
Capital/Financing Update Classification · 90% confidence The document is a company announcement regarding the extension (by annex) of a commercial production contract between Mabion S.A. and Novavax. It provides details about contractual arrangements and business cooperation but does not contain financial data, share transactions, governance changes, or regulatory compliance information. It is a corporate update on contract extension, which best fits under Capital/Financing Update (CAP) since it relates to a commercial production agreement extension that impacts company operations and revenue arrangements. The document is short (~1099 characters) and contains substantive content, not just a report publication or certification.
2026-06-18 Polish
Zawarcie umowy z Oddifact SAS regulującej pierwszy etap współpracy w zakresie zbadania możliwości zastosowania leku MabionCD20 w obszarze chorób sierocych oraz decyzja o odwróceniu odpisu aktualizu...
Regulatory Filings Classification · 95% confidence The document is titled 'Current Report No. 13/2026' and references a specific current report number and regulatory basis (Article 17(1) of the MAR Regulation - confidential information). It announces the conclusion of an agreement regarding cooperation on drug development and the reversal of an impairment charge on assets related to the MabionCD20 project. It provides an update about a transaction and business development rather than full financial statements or detailed financial results. The document length is relatively short (3301 characters) and it provides specific corporate updates rather than a comprehensive financial report. This aligns with a Regulatory Filing (RNS) classification, which covers miscellaneous regulatory announcements that do not fit into other specific categories like Annual Report, Earnings Release, or Capital/Financing Update.
2026-06-16 English
Zawarcie umowy z Oddifact SAS regulującej pierwszy etap współpracy w zakresie zbadania możliwości zastosowania leku MabionCD20 w obszarze chorób sierocych oraz decyzja o odwróceniu odpisu aktualizu...
Regulatory Filings Classification · 95% confidence The document is a current report referencing a previous report (nr 9/2026) announcing the signing of a letter of intent regarding collaboration with Oddifact SAS. The content details that on June 16, 2026, a cooperation agreement was signed for the first stage of the collaboration program related to the development and regulatory consultation for the MabionCD20 drug with the U.S. FDA. The document also discusses an accounting reversal regarding inventory valuation related to this project, and mentions that further progress will be reported in separate ongoing current reports. There is no presentation material, financial statements, nor an earnings announcement. This is a formal update on collaboration contract signing and a related financial adjustment, characteristic of regulatory current reports serving as ongoing disclosures rather than full financial reports or presentations. The descriptive language and content clearly indicate this is a Regulatory Filing (RNS) as it reports a material event update without qualifying as an Annual Report, Earnings Release or Management Discussion. Also, the document length (2522 chars) and style matches announcements typical in regulatory filings rather than comprehensive reports or presentations.
2026-06-16 Polish
Wykaz akcjonariuszy posiadających co najmniej 5% liczby głosów na Zwyczajnym Walnym Zgromadzeniu Mabion S.A. w dniu 15 czerwca 2026 roku
Major Shareholding Notification Classification · 95% confidence The document lists shareholders holding at least 5% voting rights at a General Meeting along with their respective voting percentages. This is characteristic of a Major Shareholding Notification which informs about significant ownership stakes crossing predefined thresholds. There is no indication that this is a full financial or management report, just a shareholder threshold disclosure.
2026-06-15 Polish
Wykaz akcjonariuszy posiadających co najmniej 5% głosów na Zwyczajnym Walnym Zgromadzeniu Spółki w dniu 15 czerwca 2026 r. - Content (EN)
Major Shareholding Notification Classification · 100% confidence The document is titled as a report about the list of shareholders holding at least 5% of votes at the Annual General Meeting, prepared pursuant to a specific section of law concerning shareholders' vote percentages. It specifically mentions the shareholders with significant voting rights (5% or more) at the AGM held on 15 June 2026. This matches the definition for "Major Shareholding Notification" as it informs about changes or confirmations of significant share ownership thresholds and voting rights. The length is short and it's clearly a notification rather than full financial or management reporting. Therefore, the most appropriate classification is MRQ (Major Shareholding Notification).
2026-06-15 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.